ADC Therapeutics SA logo
ADC Therapeutics SA ADCT
$ 4.13 -5.06%

Annual report 2022
added 12-21-2024

report update icon

ADC Therapeutics SA Book Value 2011-2026 | ADCT

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.
What is included in book value
  • Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
  • Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
Features of the metric
  • Assessment of the company's "real" value
    Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
  • Comparison with market capitalization
    Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
  • Indicator of financial stability
    If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
  • Key component for financial ratios
    Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value ADC Therapeutics SA

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
88.7 M 166 M 336 M 111 M 126 M 249 M 141 M - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
336 M 88.7 M 174 M

Quarterly Book Value ADC Therapeutics SA

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - 163 M 166 M 187 M 244 M 298 M 336 M - - - 111 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
336 M 111 M 215 M

Book Value of other stocks in the Biotechnology industry

Issuer Book Value Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
49 M - 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
11.8 M $ 0.79 -1.15 % $ 4.31 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
967 M $ 3.49 0.58 % $ 1.04 B canadaCanada
Frequency Therapeutics Frequency Therapeutics
FREQ
51.4 M - - $ 528 M usaUSA
argenx SE argenx SE
ARGX
5.5 B $ 700.45 -1.19 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
5.63 B - - $ 866 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
5.36 M - -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
253 M - - $ 40.3 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
35.5 M $ 3.6 1.41 % $ 8.66 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
34.9 M - -13.47 % $ 169 M franceFrance
Grifols, S.A. Grifols, S.A.
GRFS
8.61 B $ 7.81 -2.01 % $ 6.83 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
715 M - - $ 1.01 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-163 M $ 225.98 -1.32 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
29.5 M - - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
2.33 B - -1.52 % $ 24.7 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
750 M - - $ 3.67 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
70.7 M - - $ 86.2 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
8.32 M - -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
234 M - 0.23 % $ 488 M usaUSA
Advaxis Advaxis
ADXS
16.6 M - -9.65 % $ 45.9 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
18.9 M - 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
54.4 M - 10.36 % $ 9.8 M usaUSA
BioCardia BioCardia
BCDA
-1.6 M $ 1.26 -0.79 % $ 26.7 M usaUSA
AlloVir AlloVir
ALVR
113 M - 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
60.8 M - - $ 10.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
10.6 M - - - russiaRussia
Anika Therapeutics Anika Therapeutics
ANIK
271 M $ 14.2 -0.7 % $ 208 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-4.54 M - -45.71 % $ 1.2 M canadaCanada
Acer Therapeutics Acer Therapeutics
ACER
-16.8 M - 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
382 M - 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
13.2 M - 5.93 % $ 314 M canadaCanada
Athersys Athersys
ATHX
60.2 M - 3.77 % $ 22.4 M usaUSA
BioNTech SE BioNTech SE
BNTX
19.2 B $ 91.19 1.21 % $ 27.2 B germanyGermany
Aptinyx Aptinyx
APTX
38.3 M - -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
1.86 M - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
427 M $ 1.44 -1.37 % $ 367 M britainBritain
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
214 M $ 6.68 -4.57 % $ 183 M israelIsrael
Acasti Pharma Acasti Pharma
ACST
66.6 M - 4.01 % $ 150 M canadaCanada
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
45.9 M - - $ 521 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
1.66 B $ 7.92 1.67 % $ 1.31 B britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.77 M - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
124 M $ 2.54 -5.22 % $ 16 M usaUSA
Certara Certara
CERT
1.06 B $ 6.67 1.6 % $ 1.07 B usaUSA
Athira Pharma Athira Pharma
ATHA
44.8 M - - $ 269 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
20.3 M $ 3.6 -4.0 % $ 7.83 B israelIsrael
CureVac N.V. CureVac N.V.
CVAC
688 M - - $ 867 M germanyGermany
Aravive Aravive
ARAV
10.7 M - -13.39 % $ 1.45 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-7.76 M - -2.5 % $ 5.88 M usaUSA